General Information


We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. We are initially focused on novel antibody constructs for immuno-oncology, ophthalmology, and autoimmunity. By leveraging our proprietary DiversImmune and MultiMab antibody discovery and engineering platforms, we are developing a pipeline of potentially best-in-class antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Our two lead product candidates, ABP-100 and ABP-201, feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different targets with two distinct binding sites per target.


Employees: 42
Founded: 2004
Contact Information
Address 68 Cummings Park Drive, Woburn, MA 01801, US
Phone Number (617) 225-0808
Web Address http://www.abpro.com
View Prospectus: Abpro
Financial Information
Market Cap $281.25mil
Revenues $2.2 mil (last 12 months)
Net Income $-12.3 mil (last 12 months)
IPO Profile
Symbol ABP
Exchange NASDAQ
Shares (millions): 4.0
Price range $14.00 - $16.00
Est. $ Volume $60.0 mil
Manager / Joint Managers UBS Investment Bank/ Wells Fargo Securities
CO-Managers Nomura/ Oppenheimer
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change